MAPK3
MOLECULAR TARGETmitogen-activated protein kinase 3
MAPK3 (mitogen-activated protein kinase 3) is targeted by 8 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting MAPK3
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | plumbagin [Supplementary Concept] | 2.40 | 10 |
| 2 | pd98059 | 1.39 | 3 |
| 3 | alsterpaullone | 0.69 | 1 |
| 4 | isorhamnetin-3-O-beta-D-glucopyranosyl-(1-3)-alpha-L-rhamnopyranosyl-(1-6)-beta-D-galactopyranoside [Supplementary Concept] from | 0.69 | 1 |
| 5 | kenpaullone | 0.69 | 1 |
| 6 | Sorafenib | 0.69 | 1 |
| 7 | trametinib | 0.69 | 1 |
| 8 | withaferin | 0.69 | 1 |
About MAPK3 as a Drug Target
MAPK3 (mitogen-activated protein kinase 3) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 8 compounds with documented MAPK3 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
MAPK3 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.